News
PHRRF
0.048
-3.81%
-0.002
Weekly Report: what happened at PHRRF last week (0511-0515)?
Weekly Report · 2d ago
PharmaTher affiliate Sairiyo Therapeutics explores PD-001 cepharanthine for hantavirus
PUBT · 05/13 14:18
PharmaTher unit Sairiyo targets Phase 1 study of PD-001 for hantavirus
PUBT · 05/13 14:12
Weekly Report: what happened at PHRRF last week (0504-0508)?
Weekly Report · 05/11 09:41
Weekly Report: what happened at PHRRF last week (0427-0501)?
Weekly Report · 05/04 09:40
Weekly Report: what happened at PHRRF last week (0420-0424)?
Weekly Report · 04/27 09:41
PharmaTher says U.S. executive order boosts strategic value of ketamine portfolio
PUBT · 04/21 12:11
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
Newsfile · 04/21 12:00
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
Newsfile · 04/20 12:00
Weekly Report: what happened at PHRRF last week (0413-0417)?
Weekly Report · 04/20 09:40
PharmaTher backs proposed US peptide reclassification, cites upside for microneedle patch platforms
PUBT · 04/16 12:04
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Newsfile · 04/16 12:00
PharmaTher Files U.S. Patent to Bolster Peptide Microneedle Patch Platform
TipRanks · 04/13 13:28
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Newsfile · 04/13 12:00
Weekly Report: what happened at PHRRF last week (0406-0410)?
Weekly Report · 04/13 09:41
Weekly Report: what happened at PHRRF last week (0330-0403)?
Weekly Report · 04/06 09:41
Weekly Report: what happened at PHRRF last week (0323-0327)?
Weekly Report · 03/30 09:41
PharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
TipRanks · 03/26 13:21
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Newsfile · 03/26 12:00
Weekly Report: what happened at PHRRF last week (0316-0320)?
Weekly Report · 03/23 09:39
More
Webull provides a variety of real-time PHRRF stock news. You can receive the latest news about Pharmather Holdings Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PHRRF
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases. The Company is in the development of programs for the delivery of KETARX (ketamine) in a patch and on-body pump for mental health, pain and medical countermeasures indications.